Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Operates as a biotechnology company.
Year Established: | |
Funding: | |
Address: | San Diego, CA 92121 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | (858) 352-4602 |
Mail: | proteins@pfenex.com |
Company URL: | http://www.pfenex.com |
Dow Chemical Company, The,Signet Healthcare Partners (FKA: Sanders Morris Harris)
Bertrand C. Liang, M.D., M.B.A. Chief Executive Officer Dr. Bertrand C. Liang is the Managing and Executive Director of LCC Ventures, an advisory company in the biotech, pharma and venture areas. He was previously Vice Chairman, Paramount Biosciences, LLC, where he led the private equity activities, including licensing, investments and internal development capabilities of the seven global offices, from Shanghai to London. He was President, CEO and Director of Tracon Pharmaceuticals, Inc., an oncology-focused development company located in San Diego; previously, he was Vice President, New Ventures at Biogen Idec. Prior to the merger of the Biogen and Idec companies, he was Vice President, Development, managing the Hematology and Oncology portfolio, including biologics such as Rituxan and Zevalin, as well as small molecules. Subsequent to the merger, he became the Site Head of Development (preclinical and clinical) in San Diego prior to being in the corporate venture capital group, which was partnered with MPM Capital, one of the largest global life science focused funds. Dr. Liang joined Idec from Amgen, where he led the development of various cytokines and proteins, including the clinical development and launch of Neulasta